MedPath

Plasma Protein Levels and Very Preterm Birth

Completed
Conditions
Very Preterm Infants
Registration Number
NCT02007902
Lead Sponsor
Centre Hospitalier Universitaire de la Réunion
Brief Summary

The primary aim of this study is to investigate the relationship between early plasma protein levels and hemodynamics in very preterm infants during postnatal transition. Secondary aims are the following: i) to evaluate maternal and neonatal factors affecting plasma protein level at birth; ii) to evaluate the relationship between plasma protein level and albumin level on the first day of life; iii) to evaluate the association between early hypoproteinemia and neonatal mortality and morbidity in very preterm infants.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
125
Inclusion Criteria
  • Parents written informed consent
  • Birth at less than 32 weeks of gestational age
  • Birth in a III level delivery facility at Reunion Island
Exclusion Criteria
  • Major congenital abnormalities

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Evidence of clinical hemodynamic disturbances defined by arterial hypotension (non-invasive measure of MAP - mmHg - pathological for gestational age) or measured at organ colour doppler, echocardiography or NIRSabout 6 hours after birth
Secondary Outcome Measures
NameTimeMethod
plasma proteinat 1 second after birth (cord blood sample)

plasma protein level on cord blood sample depending on maternal and neonatal variables

Albumin levelAt 12 hours after birth
Mortality ratepatients will be followed for the duration of hospital stay, that is an average of 8 weeks

Trial Locations

Locations (2)

Centre Hopsitalier Universitaire de La Réunion

🇫🇷

Saint Denis, La Réunion, France

Centre Hospitalier de La Réunion

🇫🇷

Saint Pierre, La Réunion, France

Centre Hopsitalier Universitaire de La Réunion
🇫🇷Saint Denis, La Réunion, France

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.